CLINICAL_TRIALS
trial_result
· 2013-07-17
Clinical Trial Update: ToleroMune House Dust Mites (HDM) Exposure Chamber Study [Phase 2]
Summary
A Phase 2 trial of ToleroMune for rhinoconjunctivitis using a house dust mite exposure chamber has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Circassia Limited | Conditions: Rhinoconjunctivitis | Phase 2 | Status: COMPLETED